| 1 |
35489775 | Co-treatment of Low Dose Pacritinib, a Phase III Jak2 Inhibitor, Greatly Increases Apoptosis of P-gp Over-expressing Cancer Cells With Multidrug Resistance. | 2022 May |
3 |
| 2 |
31102119 | Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. | 2020 Apr |
2 |
| 3 |
31740922 | A novel human colon signet-ring cell carcinoma organoid line: establishment, characterization and application. | 2020 Jul 14 |
1 |
| 4 |
32198525 | Management of myelofibrosis after ruxolitinib failure. | 2020 Jun |
1 |
| 5 |
33232476 | Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. | 2020 Nov 24 |
1 |
| 6 |
33275766 | Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. | 2020 Dec 8 |
5 |
| 7 |
30675650 | New Concepts of Treatment for Patients with Myelofibrosis. | 2019 Jan 24 |
1 |
| 8 |
31560729 | Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. | 2019 |
2 |
| 9 |
29235894 | Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. | 2018 Apr |
1 |
| 10 |
29382747 | Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. | 2018 Feb 13 |
2 |
| 11 |
29616317 | Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. | 2018 Aug |
2 |
| 12 |
29743719 | Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. | 2018 Nov |
2 |
| 13 |
29785143 | Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis. | 2018 |
2 |
| 14 |
30001163 | Pacritinib to treat myelofibrosis patients with thrombocytopenia. | 2018 Sep |
1 |
| 15 |
28336242 | Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. | 2017 May |
1 |
| 16 |
28395559 | Management of myelofibrosis: JAK inhibition and beyond. | 2017 May |
1 |
| 17 |
28441920 | Investigational Janus kinase inhibitors in development for myelofibrosis. | 2017 Jun |
1 |
| 18 |
28500170 | JAK2 inhibitors for myeloproliferative neoplasms: what is next? | 2017 Jul 13 |
1 |
| 19 |
28576879 | Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. | 2017 Jul 27 |
1 |
| 20 |
29253028 | The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. | 2017 |
2 |
| 21 |
27180268 | Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer. | 2016 Jun 10 |
3 |
| 22 |
27226728 | Emerging treatment options for myelofibrosis: focus on pacritinib. | 2016 |
1 |
| 23 |
27334834 | Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia. | 2016 Dec 15 |
1 |
| 24 |
27541357 | Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. | 2016 Sep 22 |
2 |
| 25 |
27574472 | Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. | 2016 |
4 |
| 26 |
27598824 | The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. | 2016 Nov |
1 |
| 27 |
27931243 | Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. | 2016 Dec 8 |
3 |
| 28 |
25600203 | Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans. | 2015 |
2 |
| 29 |
25762180 | Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. | 2015 Apr 23 |
9 |
| 30 |
26288713 | Clinical potential of pacritinib in the treatment of myelofibrosis. | 2015 Aug |
1 |
| 31 |
26367195 | A comprehensive review of pacritinib in myelofibrosis. | 2015 |
1 |
| 32 |
26389774 | Pacritinib: a new agent for the management of myelofibrosis? | 2015 |
1 |
| 33 |
24746271 | The role of pacritinib in the management of myelofibrosis. | 2014 Jun |
1 |
| 34 |
25170285 | Profile of pacritinib and its potential in the treatment of hematologic disorders. | 2014 |
3 |
| 35 |
23442043 | Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. | 2013 Jun |
2 |
| 36 |
24066969 | Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. | 2013 Dec |
1 |
| 37 |
24101258 | The new landscape of therapy for myelofibrosis. | 2013 Dec |
1 |
| 38 |
22527961 | Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3). | 2012 Apr |
4 |
| 39 |
22829971 | The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. | 2012 May |
4 |
| 40 |
22965964 | Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. | 2012 Nov 20 |
3 |
| 41 |
21691275 | SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. | 2011 Nov |
10 |
| 42 |
22829080 | Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. | 2011 Nov |
6 |